SCHEMBL3014724

SCHEMBL3014724

O=S(=O)(c1ccc(Cl)cc1)C1CCN(c2nc(Cc3ccccc3)cs2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 4/20 0.46
KCNH2 Q12809 3/20 0.42
HTR2C P28335 2/20 0.42
MAPT P10636 2/20 0.41
NPC1 O15118 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
RAB9A P51151 1/20 0.41
GBA1 P04062 1/20 0.39
HTT P42858 1/20 0.39
LMNA P02545 2/20 0.38
GAA P10253 1/20 0.38
DRD2 P14416 1/20 0.37
MEN1 O00255 1/20 0.37
MAPK1 P28482 1/20 0.37
KMT2A Q03164 1/20 0.37
FFAR2 O15552 1/20 0.36
PTGER1 P34995 1/20 0.36
ACHE P22303 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017031 0.95 MAPT (0.42) HTR2AKCNH2HTR2CMAPTNPC1
SCHEMBL3015946 0.92 HTR2A (0.44) HTR2AKCNH2HTR2CMAPTNPC1
SCHEMBL3010926 0.91 MAPT (0.40) HTR2AKCNH2HTR2CMAPTNPC1
SCHEMBL3021897 0.90 HTR2A (0.45) HTR2AKCNH2HTR2CMAPTNPC1
SCHEMBL3018372 0.90 MAPT (0.39) HTR2AKCNH2HTR2CMAPTGBA1
SCHEMBL3008320 0.90 MAPT (0.39) HTR2AKCNH2HTR2CMAPTNPC1
SCHEMBL3011786 0.90 MAPT (0.39) HTR2AKCNH2HTR2CMAPTNPC1
SCHEMBL3001231 0.90 MAPT (0.42) HTR2AKCNH2HTR2CMAPTNPC1
SCHEMBL3011260 0.90 MAPT (0.42) HTR2AKCNH2HTR2CMAPTNPC1
SCHEMBL3015982 0.90 HTR2A (0.44) HTR2AKCNH2HTR2CMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA HTR2A 752/4885KCNH2 3130/4885HTR2C 1153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.